Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Varenicline decreases alcohol consumption in heavy-drinking smokers.

Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL.

Psychopharmacology (Berl). 2012 Oct;223(3):299-306. doi: 10.1007/s00213-012-2717-x. Epub 2012 May 1.

2.

A preliminary investigation of varenicline for heavy drinking smokers.

Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS.

Psychopharmacology (Berl). 2011 Jun;215(4):655-63. doi: 10.1007/s00213-010-2160-9. Epub 2011 Jan 11.

3.

Varenicline reduces alcohol self-administration in heavy-drinking smokers.

McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E.

Biol Psychiatry. 2009 Jul 15;66(2):185-90. doi: 10.1016/j.biopsych.2009.01.029. Epub 2009 Feb 27.

4.

Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial.

Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL.

J Clin Psychopharmacol. 2013 Apr;33(2):243-7. doi: 10.1097/JCP.0b013e3182870551.

PMID:
23422399
5.

Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED.

Psychopharmacology (Berl). 2014 Oct;231(19):3843-53. doi: 10.1007/s00213-014-3519-0. Epub 2014 Apr 15.

7.
8.

Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals.

Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H.

Psychopharmacology (Berl). 2014 Sep;231(18):3799-807. doi: 10.1007/s00213-014-3518-1. Epub 2014 Mar 20.

9.
10.

Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.

Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR.

Arch Intern Med. 2011 Apr 25;171(8):770-7. doi: 10.1001/archinternmed.2011.138.

PMID:
21518946
11.

A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.

Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R; NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group.

J Addict Med. 2013 Jul-Aug;7(4):277-86. doi: 10.1097/ADM.0b013e31829623f4.

12.

The effects of varenicline on attention and inhibitory control among treatment-seeking smokers.

Rhodes JD, Hawk LW Jr, Ashare RL, Schlienz NJ, Mahoney MC.

Psychopharmacology (Berl). 2012 Sep;223(2):131-8. doi: 10.1007/s00213-012-2700-6. Epub 2012 Apr 12.

PMID:
22526531
13.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789
14.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
15.

Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.

Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA.

J Psychopharmacol. 2012 Oct;26(10):1383-90. doi: 10.1177/0269881112449397. Epub 2012 Jun 13.

16.

Effects of varenicline on smoking cue–triggered neural and craving responses.

Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, Detre JA, O'Brien CP, Childress AR.

Arch Gen Psychiatry. 2011 May;68(5):516-26. doi: 10.1001/archgenpsychiatry.2010.190. Epub 2011 Jan 3.

17.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
18.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.

19.

Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.

Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, McFarland N, Thabane L, McIvor A, Zeidler J, Smieja M.

AIDS Patient Care STDS. 2012 Jan;26(1):12-9. doi: 10.1089/apc.2011.0199. Epub 2011 Oct 18.

20.

Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.

Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, Levine MD, George TP.

J Clin Psychiatry. 2014 Jul;75(7):765-72. doi: 10.4088/JCP.13m08756.

PMID:
25006684

Supplemental Content

Support Center